As of close of business last night, Adaptive Biotechnologies Corp’s stock clocked out at $3.18, down -1.85% from its previous closing price of $3.24. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 1118440 shares were traded.
Ratios:
To gain a deeper understanding of ADPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.71.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $15.
Piper Sandler Upgraded its Neutral to Overweight on December 21, 2022, whereas the target price for the stock was revised from $7.50 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when ROBINS CHAD M sold 48,673 shares for $3.43 per share. The transaction valued at 167,007 led to the insider holds 2,576,701 shares of the business.
RUBINSTEIN JULIE sold 39,070 shares of ADPT for $135,764 on Mar 05 ’24. The President now owns 472,754 shares after completing the transaction at $3.47 per share. On Mar 05 ’24, another insider, BENZENO SHARON, who serves as the Chief Commercial Ofc Imm Med of the company, sold 29,390 shares for $3.44 each. As a result, the insider received 100,994 and left with 327,415 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 470.10M and an Enterprise Value of 222.47M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.71 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 1.31 whereas that against EBITDA is -1.18.
Stock Price History:
Over the past 52 weeks, ADPT has reached a high of $9.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 3.9352, while the 200-Day Moving Average is calculated to be 5.3661.
Shares Statistics:
It appears that ADPT traded 1.46M shares on average per day over the past three months and 1.68M shares per day over the past ten days. A total of 145.08M shares are outstanding, with a floating share count of 138.51M. Insiders hold about 4.54% of the company’s shares, while institutions hold 95.40% stake in the company. Shares short for ADPT as of Feb 29, 2024 were 8.77M with a Short Ratio of 5.99, compared to 8.81M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.04% and a Short% of Float of 7.75%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.37, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.31 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.29 and -$1.37 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.06, with 6 analysts recommending between -$0.65 and -$1.29.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $38.21M. It ranges from a high estimate of $40M to a low estimate of $34.8M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $37.65M, an estimated increase of 1.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $183.4M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $175.61M. In the same quarter a year ago, actual revenue was $170.28M, up 3.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $220.99M in the next fiscal year. The high estimate is $256.8M and the low estimate is $195.5M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
